WilliamKevinKellyDO

Genitourinary Oncology

Professor, Medical Oncology and Urology Chair, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University Associate Director of Clinical Research, SIdney Kimmel Cancer Center

Join to view full profile

Dr. Kelly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kelly's full profile

Already have an account?

Office
1025 Walnut St
Ste 700
Philadelphia, PA 19107

Summary

Dr. William Kelly is a genitourinary oncologists with over 30 years of experience treating patients with prostate cancer, testicular cancer, bladder cancer and kidney cancer. He is affiliated with Thomas Jefferson University and the Sidney Kimmel Cancer Center.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1987 - 1990
Philadelphia College of Osteopathic MedicineClass of 1986

Certifications & Licensure

NY State License 1990 - 2027
PA State License 1987 - 2026
DE State License 2017 - 2025
NJ State License 2017 - 2025
CT State License 2005 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Start of enrollment: 1998 Apr 01
Completed
Phase 1, Phase 2
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Start of enrollment: 2000 Jan 01
Completed
Phase 1
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 2
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Start of enrollment: 2001 Jul 01
Completed
Phase 1
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2006 Jun 01
Completed
Phase 1
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Start of enrollment: 2011 Sep 22
Completed
Phase 1
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2012 Oct 04
Active, not recruiting
Phase 1
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Start of enrollment: 2013 Aug 14
Completed
Phase 1, Phase 2
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer Start of enrollment: 2014 Apr 02
Active, not recruiting
Phase 1
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) Start of enrollment: 2017 Sep 22
Completed
Phase 1
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Roles: Contact
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Start of enrollment: 2017 Mar 01
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
Nicole M Naranjo, Anne Kennedy, Anna Testa, Cecilia E Verrillo, Adrian D Altieri
Cancer Biology & Therapy. 2024-12-31
Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2.
Cecilia E Verrillo, Fabio Quaglia, Christopher D Shields, Stephen Lin, Andrew V Kossenkov
Journal of Extracellular Vesicles. 2024-08-01
3 citations
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji
Cancer Research Communications. 2024-08-01

Journal Articles

Germline Genetic Testing for Inherited Prostate Cancer in Practice: Implications for Genetic Testing, Precision Therapy, and Cascade Testing
Colette Hyatt, William K Kelly, Veda N Giri, Leonard G Gomella, Karen E Knudsen, The Prostate